Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2004
Business Overview: The company designs, develops, manufactures, and distributes life science instrumentation and consumables. Its growth strategy relies on new product development, strategic partnerships, and acquisitions. A significant portion of revenue (31% in Q1 2004) is derived from capital equipment, which introduces seasonality and volatility to quarterly results.
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenues | $22,165 | $19,473 |
| Net Income (Loss) | $(51) | $776 |
| Operating Income | $163 | $1,221 |
| Gross Margin % | 47.9% | 50.5% |
| Cash from Operations | $1,501 | $677 |
| Cash and Equivalents (End of Period) | $9,773 | $9,321 |
| Total Debt (Current + Long-term) | $19,783 | $13,185 |
| Working Capital | $42,384 | $40,182 |
Note: Debt figures include current installments of long-term debt ($396k) and long-term debt less current installments ($19,387k) as of March 31, 2004.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14% ($2.7 million) year-over-year, driven primarily by acquisitions made since March 2003 (BioRobotics, Hoefer, KD Scientific) and favorable foreign exchange rates (strengthening of the British pound and Euro).
- Profitability Decline: The company reported a net loss of $51,000 compared to net income of $776,000 in the prior year. Operating income dropped significantly from $1.2 million to $163,000.
- Margin Compression: Gross margin decreased from 50.5% to 47.9%. This was attributed to an 11% gross margin drop at the Genomic Solutions subsidiary due to lower volumes and a higher mix of distributor sales, as well as fair value adjustments on acquired inventory.
- Expense Increases:
- Cost of Product Revenues: Increased 20% ($1.9 million), partly due to $302,000 in fair value adjustments for acquired inventory.
- Amortization: Increased 48% ($0.3 million) to $923,000 due to new intangible assets from acquisitions.
- Interest Expense: Shifted from net interest income of $27,000 in 2003 to net interest expense of $124,000 in 2004 due to increased debt usage for acquisitions.
- Acquisition Activity: The company acquired KD Scientific, Inc. on March 3, 2004, for approximately $6.86 million, funded by a drawdown on its credit facility.
Guidance, Outlook, and Risks
- Outlook: Management expects revenue growth without further acquisitions to be below historic levels. An action plan is expected to be implemented in Q2 2004 to improve operating metrics for genomics, proteomics, and high-throughput screening lines, which may adversely impact Q2 earnings.
- Liquidity and Capital: The company has a $20 million credit facility with Brown Brothers Harriman, with approximately $19.4 million drawn as of May 2004. Management believes resources are sufficient for at least 12 months. However, the company is currently unable to access public equity markets due to a delinquent Form 8-K amendment, limiting capital raising to private transactions or additional borrowing.
- Legal Proceedings: A pending appeal by Paul D. Grindle regarding a 1996 asset purchase. The company prevailed in arbitration and Superior Court, but the matter is pending before the Massachusetts Appeals Court. Grindle originally sought $15 million in damages.
- Key Risks:
- Integration Risk: Difficulty integrating recent acquisitions (KD Scientific, Hoefer, BioRobotics) could delay anticipated benefits.
- Customer Concentration: Significant reliance on Amersham Biosciences as a distributor (approx. 19% of revenue); termination of this agreement could materially harm the business.
- Market Volatility: Dependence on capital equipment sales creates seasonal fluctuations and sensitivity to economic downturns in the pharmaceutical and biotechnology sectors.
- Goodwill Impairment: Goodwill and indefinite-lived intangibles totaled $38.6 million (28% of total assets). Future impairment charges could adversely affect net income.
Investor Verification Checklist
- Form 8-K Status: Verify the resolution of the outstanding Form 8-K amendment to confirm when the company regains access to public equity markets (Form S-3 eligibility).
- Acquisition Integration: Monitor the Q2 and Q3 2004 results to assess the financial impact of the KD Scientific, Hoefer, and BioRobotics acquisitions and the success of the planned "action plan" for Genomic Solutions.
- Debt Covenants: Review compliance with the $20 million credit facility covenants (income, debt coverage, working capital), especially given the high utilization rate (~97%).
- Legal Appeal: Track the status of the Grindle appeal in the Massachusetts Appeals Court to assess potential liability exposure.
- Distributor Relationship: Monitor the stability of the distribution agreement with Amersham Biosciences, particularly following General Electric's acquisition of Amersham plc.